Orchid Pharma Ltd (ORCHPHARMA) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Orchid Pharma reported a 29% decline in sales for Q1 FY26, reaching INR 173 crores compared to INR 244 crores in the same period last year, attributed to a global slowdown in the antibiotics market.
- The company maintained gross margins at approximately 42% despite market pressures by focusing on disciplined pricing and a resilient product mix.
- Operational EBITDA for the quarter was INR 14 crores.
- Orchid Pharma acquired global rights to Enmetazobactam and the Exblifep trademark from Allecra, positioning itself as the sole Indian innovator of an internationally approved new chemical entity.
- The company's domestic brand, Orblicef, demonstrated steady performance, supported by Cipla's hospital network and Orchid's AMS division.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.